Table A4.12 Threshold analysis to identify the extreme values of the utility scores that would make the ICER for SRT cost-effective (i.e. < £20,000), with questionable cost-effectiveness (i.e. £20,000–£30.000), or no cost-effective (i.e. > £30,000) when compared to RT alone.

Utility valuesICER: ∆ cost / ∆ QALYs
AmbulantNon-ambulant
Base-case:
0.70.117,117
Threshold analyses:
0.7≥ 0.4317≥ 20000
≤ 0.60330.1≥ 20000
0.7SNF≥ 30000
≤ 0.41190.1≥ 30000

SNF = Solution not found

From: Appendix 4, An economic evaluation of treatments for people with suspected metastatic spinal cord compression

Cover of Metastatic Spinal Cord Compression
Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression.
NICE Clinical Guidelines, No. 75.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.